279 related articles for article (PubMed ID: 32653521)
1. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T
Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521
[TBL] [Abstract][Full Text] [Related]
2. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
3. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.
Wang J; Zhang K; Wang J; Wu X; Liu X; Li B; Zhu Y; Yu Y; Cheng Q; Hu Z; Guo C; Hu S; Mu B; Tsai CH; Li J; Smith L; Yang L; Liu Q; Chu P; Chang V; Zhang B; Wu M; Jiang X; Yen Y
Oncotarget; 2015 Aug; 6(22):18905-20. PubMed ID: 26056085
[TBL] [Abstract][Full Text] [Related]
4. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
5. Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma.
Liu Z; Zhou K; Zeng J; Zhou X; Li H; Peng K; Liu X; Li F; Jiang B; Zhao M; Ma T
Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35856436
[TBL] [Abstract][Full Text] [Related]
6. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1.
Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
[TBL] [Abstract][Full Text] [Related]
7. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
8. COUP-TFII promotes metastasis and epithelial-to-mesenchymal transition through upregulating Snail in human intrahepatic cholangiocarcinoma.
Lang Q; Xiao P; Zhao M; Liang D; Meng Q; Pei T
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1247-1256. PubMed ID: 33166992
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
10. miR-204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells.
Qiu YH; Wei YP; Shen NJ; Wang ZC; Kan T; Yu WL; Yi B; Zhang YJ
Cell Physiol Biochem; 2013; 32(5):1331-41. PubMed ID: 24280681
[TBL] [Abstract][Full Text] [Related]
11. Mortalin promotes cell proliferation and epithelial mesenchymal transition of intrahepatic cholangiocarcinoma cells in vitro.
Kang Q; Cai JB; Dong RZ; Liu LX; Zhang C; Zhang PF; Zou H; Xie N; Zhang L; Zhang XY; Song ZJ; Dong ZR; Hu MY; Huang XY; Zhang XW; Ke AW; Shi GM
J Clin Pathol; 2017 Aug; 70(8):677-683. PubMed ID: 28096273
[TBL] [Abstract][Full Text] [Related]
12. LncRNA-CCAT1 Promotes Migration, Invasion, and EMT in Intrahepatic Cholangiocarcinoma Through Suppressing miR-152.
Zhang S; Xiao J; Chai Y; Du YY; Liu Z; Huang K; Zhou X; Zhou W
Dig Dis Sci; 2017 Nov; 62(11):3050-3058. PubMed ID: 28921383
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
14. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
[TBL] [Abstract][Full Text] [Related]
16. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
17. M
Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
[TBL] [Abstract][Full Text] [Related]
18. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma.
Ohashi T; Eguchi H; Kawamoto K; Konno M; Asai A; Colvin H; Ueda Y; Takaoka H; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Kobayashi S; Koseki J; Satoh T; Ogawa K; Doki Y; Mori M; Ishii H
Oncol Rep; 2018 Mar; 39(3):1276-1282. PubMed ID: 29286150
[TBL] [Abstract][Full Text] [Related]
20. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
